AXGN NASDAQ
AxoGen, Inc.
1W: -13.8%
1M: -22.6%
3M: -18.7%
YTD: +20.6%
1Y: +109.2%
3Y: +647.8%
5Y: +132.4%
$37.39
-2.53 (-6.34%)
Weekly Expected Move ±8.2%
$31
$34
$37
$40
$44
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (61)
Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair
3 Emerging Biotech Stocks With Significant Upside Potential
313,399 Shares in AxoGen, Inc. $AXGN Acquired by Bank of America Corp DE
At a glance: stocks gapping down premarket
Axogen to buy BioCircuit Technologies for $200M
Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies
Bank of New York Mellon Corp Invests $7.04 Million in AxoGen, Inc. $AXGN
Assenagon Asset Management S.A. Trims Stock Position in AxoGen, Inc. $AXGN
Axogen (AXGN) Q2 2026 Earnings Call Transcript
Arrowstreet Capital Limited Partnership Lowers Stock Holdings in AxoGen, Inc. $AXGN
AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Here are the major earnings before the open Wednesday
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Axogen outlines at least $270M 2026 revenue on at least 20% growth amid Avance biologic channel transition
Axogen (AXGN) Q3 2025 Earnings Transcript
Axogen (AXGN) Q1 2025 Earnings Transcript
Full Transcript: Axogen Q1 2026 Earnings Call
AxoGen (AXGN) Q1 Earnings Lag Estimates
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Earnings Scheduled For April 28, 2026
AxoGen Non-GAAP EPS of $0.07 in-line, revenue of $61.46M beats by $3.69M
Axogen, Inc. Reports First Quarter 2026 Financial Results
Here are the major earnings before the open Tuesday
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million
B. Metzler seel. Sohn & Co. AG Takes $1.95 Million Position in AxoGen, Inc. $AXGN
Axogen (AXGN) Q2 2025 Earnings Transcript
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
CVRx Announces Nomination of Michael Dale for Election to the Board of Directors
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
Allspring Global Investments Holdings LLC Buys Shares of 25,792 AxoGen, Inc. $AXGN
SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN
AxoGen, Inc. $AXGN Shares Sold by JPMorgan Chase & Co.
Exchange Traded Concepts LLC Sells 26,743 Shares of AxoGen, Inc. $AXGN
F&V Capital Management LLC Purchases Shares of 176,995 AxoGen, Inc. $AXGN
Assenagon Asset Management S.A. Purchases 90,777 Shares of AxoGen, Inc. $AXGN
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
Do Options Traders Know Something About Axogen Stock We Don't?
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
Axogen Q4: EPS Miss Amid Biologics Transition
Axogen targets at least 18% revenue growth in 2026 as BLA milestone strengthens market position
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
AxoGen Non-GAAP EPS of $0.07 misses by $0.03, revenue of $59.9M in-line
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) Q4 Earnings Miss Estimates
Here are the major earnings before the open Tuesday
AxoGen Q4 2025 Earnings Preview
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Wasatch Micro Cap Fund Q4 2025 Performance Review
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Axogen Announces Proposed Public Offering of Common Stock
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen CEO Axed 25,000 Shares From His Direct Holdings
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
FDA approves Axogen's nerve repair graft
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen